RxIndia
Loading clinical data...
Loading clinical data...
Verified clinical guidelines and emergency management protocols.
| Procedure/Action | Primary Care | Secondary/Tertiary Care |
|---|---|---|
| Clinical recognition |
โ
|
โ
|
| Rapid diagnostic tests (RDT) |
โ
|
โ
|
| Oral rehydration / IV fluids |
โ
|
โ
|
| Oral antimalarials |
โ
|
โ
|
| IV Artesunate (severe malaria) |
โ ๏ธ (if available)
|
โ
|
| Empiric Doxycycline (Scrub Typhus) |
โ
|
โ
|
| IV Ceftriaxone |
โ
|
โ
|
| Blood transfusion |
โ
|
โ
|
| Platelet transfusion |
โ
|
โ
|
| Dialysis |
โ
|
โ
|
| Mechanical ventilation |
โ
|
โ
|
| ICU-level care |
โ
|
โ
|
| Milestone | Target Time |
|---|---|
| Recognize warning signs |
Immediate
|
| Blood glucose check |
≤ 5 min
|
| IV access (if warning signs) |
≤ 10 min
|
| Rapid diagnostic tests |
≤ 30 min
|
| Start empiric antibiotics (if indicated) |
≤ 1 hour
|
| Start IV Artesunate (severe malaria) |
Immediate
|
| Transfer (if needed) |
ASAP after stabilization
|
| Disease | Peak Season | Region |
|---|---|---|
|
Dengue
|
Monsoon & post-monsoon (July-November) | Pan-India; urban > rural |
|
Malaria
|
Monsoon & post-monsoon (June-October) | Endemic: Odisha, Chhattisgarh, Jharkhand, NE states, MP, Maharashtra |
|
Scrub Typhus
|
Post-monsoon (September-November) | Hilly/forested: Himachal, Uttarakhand, NE states, South India |
|
Leptospirosis
|
Monsoon & post-monsoon (July-November) | Coastal: Kerala, Gujarat, Maharashtra, Andaman |
|
Enteric Fever
|
Year-round; peaks in monsoon | Pan-India; poor sanitation areas |
|
Chikungunya
|
Monsoon & post-monsoon | Pan-India (epidemic pattern) |
|
Japanese Encephalitis
|
Monsoon (July-October) | UP, Bihar, Assam, WB, Tamil Nadu (rice-growing) |
| Feature | Dengue | Malaria | Scrub Typhus | Leptospirosis | Enteric Fever |
|---|---|---|---|---|---|
|
Vector/Source
|
Aedes mosquito
|
Anopheles mosquito
|
Mite (chigger)
|
Contaminated water/soil
|
Fecal-oral
|
|
Incubation
|
4-7 days
|
7-30 days
|
6-21 days
|
5-14 days
|
7-21 days
|
|
Rash
|
Maculopapular (late)
|
โ Rare
|
โ ๏ธ(Variable) Maculopapular
|
โ ๏ธ Variable
|
Rose spots (rare)
|
|
Eschar
|
โ
|
โ
|
โ
Pathognomonic
|
โ
|
โ
|
|
Hepatosplenomegaly
|
โ ๏ธVariable
|
โ
|
โ ๏ธ๏ธ (Variable)
|
โ
|
โ
|
|
Jaundice
|
โ ๏ธ(Variable) Rare
|
โ
(severe)
|
โ ๏ธ(Variable)
|
โ
Common
|
โ ๏ธ (Variable)Rare
|
|
Conjunctival suffusion
|
โ
|
โ
|
โ
|
โ
Suggestive
|
โ
|
|
Platelet drop
|
โ
Marked
|
โ ๏ธ (Variable)Mild-moderate
|
โ ๏ธ(Variable) Mild-moderate
|
โ ๏ธ (Variable)Mild
|
โ ๏ธ(Variable) Mild
|
|
ARDS/Pulmonary
|
โ ๏ธ(Variable)
|
โ
|
โ
Common
|
โ
Hemorrhage
|
โ Rare
|
|
Specific test
|
NS1, IgM
|
Smear, RDT
|
IgM ELISA
|
IgM ELISA, MAT
|
Blood culture
|
| Action | Details |
|---|---|
|
History
|
Duration, travel, occupation, animal contact, water exposure, sick contacts |
|
Examine
|
Rash, eschar, jaundice, hepatosplenomegaly, lymphadenopathy, bleeding |
|
Vitals
|
Temperature, BP, HR, RR, SpOโ |
|
Warning signs
|
Check for each disease-specific warning sign |
|
Blood glucose
|
Rule out hypoglycemia |
| Question | Significance |
|---|---|
| Duration of fever? | < 7 days vs > 7 days |
| Travel to endemic area? | Malaria, Scrub Typhus |
| Occupation? | Farmer, sewage worker (Leptospirosis) |
| Wading through flood water? | Leptospirosis |
| Animal contact? | Leptospirosis |
| Bite/eschar noticed? | Scrub Typhus |
| Unsafe water/food? | Enteric fever |
| Mosquito exposure? | Dengue, Malaria, Chikungunya |
| Similar illness in family/area? | Epidemic (Dengue, Chikungunya) |
| Finding | Suggests |
|---|---|
|
Eschar (painless black scab)
|
Scrub Typhus
|
|
Conjunctival suffusion (redness without discharge)
|
Leptospirosis
|
|
Muscle tenderness (especially calf)
|
Leptospirosis
|
|
Relative bradycardia (HR not ↑ with fever)
|
Enteric Fever, Scrub Typhus
|
|
Severe thrombocytopenia (< 50,000)
|
Dengue
|
|
Splenomegaly prominent
|
Malaria, Enteric Fever
|
|
Altered sensorium + fever
|
Cerebral Malaria, Scrub Typhus, Leptospirosis
|
|
Jaundice + fever + renal failure
|
Leptospirosis, Severe Malaria
|
|
Pulmonary involvement (ARDS)
|
Scrub Typhus, Leptospirosis
|
|
Bleeding (petechiae, mucosal, GI)
|
Dengue
|
| Disease | Rapid Test | When Positive | Sensitivity |
|---|---|---|---|
|
Dengue
|
NS1 antigen |
Day 1-5
|
80-90%
|
| IgM antibody |
Day 5+
|
90-95%
|
|
| IgG antibody |
Day 7+ (or secondary infection)
|
Variable
|
|
|
Malaria
|
RDT (Pf/Pv) |
Any time during infection
|
90-95%
|
| Peripheral smear |
Any time
|
Gold standard
|
|
|
Scrub Typhus
|
IgM rapid test |
Day 7+
|
Variable (60-90%)
|
|
Leptospirosis
|
IgM rapid test |
Day 7+
|
Variable (50-80%)
|
|
Enteric Fever
|
Widal test |
Day 7+
|
Poor specificity
|
| Typhidot IgM |
Day 4+
|
Moderate
|
| Test | Note |
|---|---|
|
Dengue NS1
|
Best in first 5 days; negative doesn't rule out |
|
Dengue IgM
|
Becomes positive around day 5; use combo kit |
|
Malaria RDT
|
Can remain positive after treatment; smear better for follow-up |
|
Widal
|
Single titre unreliable; rising titre more useful; avoid if possible |
|
Scrub Typhus IgM
|
May be negative early; treat empirically if clinical suspicion |
| Category | Features |
|---|---|
|
Dengue without Warning Signs
|
Fever + ≥ 2 of: nausea/vomiting, rash, aches, leukopenia, positive tourniquet test |
|
Dengue with Warning Signs
|
Above + any warning sign (see below) |
|
Severe Dengue
|
Severe plasma leakage, severe bleeding, or severe organ impairment |
| Warning Sign | Indicates |
|---|---|
|
Abdominal pain or tenderness
|
Plasma leakage |
|
Persistent vomiting
|
Dehydration risk |
|
Clinical fluid accumulation
|
Pleural effusion, ascites |
|
Mucosal bleeding
|
Coagulopathy |
|
Lethargy / Restlessness
|
Impending shock |
|
Liver enlargement > 2 cm
|
Hepatic involvement |
|
Laboratory: Hct increase with rapid platelet drop
|
Hemoconcentration |
| Phase | Day | Features |
|---|---|---|
|
Febrile
|
1-3
|
High fever, headache, myalgia, rash |
|
Critical
|
4-6 (around defervescence)
|
โ ๏ธ Maximum risk of shock; plasma leakage |
|
Recovery
|
7-10
|
Fluid reabsorption; risk of fluid overload |
| Can Manage | Must Refer |
|---|---|
| Dengue without warning signs | Any warning sign present |
| Tolerating oral fluids | Severe dengue |
| Adequate urine output | Bleeding |
| Stable vitals | Shock / Hypotension |
| Hct stable | Rising Hct with falling platelets |
| Platelets > 50,000 | Platelets < 20,000 |
| Patient Type | Fluid |
|---|---|
| Tolerating orals |
ORS, coconut water, fruit juices, rice kanji
|
| Target | 2-3 liters/day orally |
| Avoid | NSAIDs (bleeding risk), Aspirin, IM injections |
| Paracetamol | 500-1000 mg every 6 hrs (max 4 g/day) |
| Step | Action |
|---|---|
| 1 |
Start IV crystalloid (NS or RL)
|
| 2 |
Initial bolus: 5-7 mL/kg/hr for 1-2 hours
|
| 3 | If improving: Reduce to 3-5 mL/kg/hr for 2-4 hrs |
| 4 | If stable: Reduce to 2-3 mL/kg/hr |
| 5 | Monitor: Vitals hourly, Hct every 4-6 hrs |
| 6 |
TRANSFER to higher centre
|
| Weight | 5 mL/kg/hr | 3 mL/kg/hr | 2 mL/kg/hr |
|---|---|---|---|
|
50 kg
|
250 mL/hr
|
150 mL/hr
|
100 mL/hr
|
|
60 kg
|
300 mL/hr
|
180 mL/hr
|
120 mL/hr
|
|
70 kg
|
350 mL/hr
|
210 mL/hr
|
140 mL/hr
|
|
80 kg
|
400 mL/hr
|
240 mL/hr
|
160 mL/hr
|
| Sign |
|---|
| Tachycardia with narrow pulse pressure (< 20 mmHg) |
| Cold, clammy extremities |
| Delayed capillary refill (> 3 seconds) |
| Weak pulse |
| Restlessness or lethargy |
| Reduced urine output |
| Step | Action |
|---|---|
| 1 |
IV crystalloid bolus 10-20 mL/kg over 15-30 min
|
| 2 | Reassess: If improving, reduce rate |
| 3 | If no improvement: Repeat bolus |
| 4 | If still no improvement: May need colloid (at higher centre) |
| 5 |
TRANSFER URGENTLY
|
| โ Avoid |
|---|
| NSAIDs (Ibuprofen, Diclofenac) – increases bleeding |
| Aspirin – increases bleeding |
| IM injections – hematoma risk |
| Excessive IV fluids in recovery phase – pulmonary edema |
| Prophylactic platelet transfusion (not indicated unless severe bleeding or < 10,000) |
| Steroids (no proven benefit) |
| Scenario | Action |
|---|---|
| No warning signs, tolerating orally | Oral fluids, Paracetamol, monitor daily |
| Warning signs |
IV fluids, TRANSFER
|
| Shock |
IV bolus 10-20 mL/kg, TRANSFER URGENTLY
|
| Category | Features |
|---|---|
|
Uncomplicated Malaria
|
Fever with positive test, no danger signs |
|
Severe Malaria
|
Any danger sign present (see below) |
| Danger Sign | Clinical Feature |
|---|---|
|
Impaired consciousness
|
GCS < 11 or unable to sit/stand/localize pain |
|
Prostration
|
Unable to walk or sit without support |
|
Multiple convulsions
|
> 2 episodes in 24 hrs |
|
Respiratory distress
|
Acidotic breathing, SpOโ < 92% |
|
Shock
|
SBP < 80 mmHg, cold extremities |
|
Severe anemia
|
Hb < 5 g/dL or Hct < 15% |
|
Jaundice
|
Visible icterus + parasitemia |
|
Significant bleeding
|
Spontaneous bleeding |
|
Hypoglycemia
|
Blood glucose < 40 mg/dL |
|
Metabolic acidosis
|
pH < 7.25 or bicarbonate < 15 |
|
Renal impairment
|
Creatinine > 3 mg/dL or oliguria |
|
Hyperparasitemia
|
> 10% parasitized RBCs (or > 250,000/μL) |
|
Pulmonary edema/ARDS
|
Radiological evidence |
|
Hemoglobinuria
|
Dark/black urine |
| Species | Prevalence | Features |
|---|---|---|
|
P. falciparum
|
~50%
|
Severe malaria, cerebral malaria, death |
|
P. vivax
|
~50%
|
Relapsing; can cause severe disease |
|
P. malariae
|
Rare
|
Chronic infection |
|
P. ovale
|
Very rare
|
Similar to vivax |
|
Mixed
|
Common
|
Both Pf and Pv |
| Test | When to Use |
|---|---|
|
RDT (Rapid Diagnostic Test)
|
First-line in primary care |
|
Peripheral smear
|
Gold standard; species identification; parasite count |
|
QBC
|
If available; sensitive |
| Drug | Dose | Duration |
|---|---|---|
|
Artesunate-Lumefantrine (AL)
|
Weight-based (see below)
|
3 days
|
|
OR Artesunate + Sulfadoxine-Pyrimethamine (AS+SP)
|
As per NVBDCP
|
3 days + single dose
|
|
+ Primaquine
|
0.25 mg/kg
|
Day 1 only (single dose for gametocidal)
|
| Weight | Tablets (20/120 mg) per dose | Doses |
|---|---|---|
|
5-14 kg
|
1 tablet
|
At 0, 8, 24, 36, 48, 60 hrs (6 doses)
|
|
15-24 kg
|
2 tablets
|
6 doses
|
|
25-34 kg
|
3 tablets
|
6 doses
|
|
≥ 35 kg
|
4 tablets
|
6 doses
|
| Drug | Dose | Duration |
|---|---|---|
|
Chloroquine
|
25 mg base/kg over 3 days (10+10+5 mg/kg)
|
3 days
|
|
+ Primaquine
|
0.25 mg/kg/day
|
14 days (for radical cure)
|
| Day | Dose (mg base/kg) |
|---|---|
|
Day 1
|
10 mg/kg
|
|
Day 2
|
10 mg/kg
|
|
Day 3
|
5 mg/kg
|
| If Chloroquine-resistant area (NE India, some parts) |
|---|
|
Use ACT (Artesunate-Lumefantrine) + Primaquine 14 days
|
| Drug | Dose | Route | Timing |
|---|---|---|---|
|
Artesunate
|
2.4 mg/kg
|
IV or IM
|
At 0, 12, 24 hrs, then every 24 hrs |
| If Artesunate unavailable: | |||
|
Artemether
|
3.2 mg/kg loading, then 1.6 mg/kg
|
IM
|
Every 24 hrs |
|
Quinine (last resort)
|
20 mg/kg loading, then 10 mg/kg
|
IV infusion
|
Every 8 hrs |
| If Artesunate Available | If Artesunate NOT Available |
|---|---|
| Artesunate 2.4 mg/kg IM/IV single dose | Artemether 3.2 mg/kg IM single dose |
| Then transfer | OR Quinine 20 mg/kg IV loading |
| โ Avoid |
|---|
| Chloroquine for P. falciparum (resistance widespread) |
| Oral treatment for severe malaria |
| Primaquine in pregnancy or G6PD deficiency |
| Delaying parenteral treatment for severe malaria |
| Scenario | Action |
|---|---|
| Uncomplicated Pf or mixed | ACT (Artesunate-Lumefantrine) × 3 days |
| Uncomplicated Pv | Chloroquine × 3 days + Primaquine × 14 days |
| Severe / Any danger sign |
Pre-referral Artesunate 2.4 mg/kg IM/IV → TRANSFER
|
| Feature | Details |
|---|---|
|
Cause
|
Orientia tsutsugamushi (rickettsial) |
|
Vector
|
Larval mites (chiggers) |
|
Incubation
|
6-21 days |
|
Classic triad
|
Fever + Eschar + Lymphadenopathy |
|
Eschar
|
Painless, black, necrotic, often in hidden areas |
|
Season
|
Post-monsoon (Sep-Nov) in India |
| Eschar Characteristics |
|---|
| Painless black scab with erythematous halo |
| 5-10 mm diameter |
| Often in hidden areas: axilla, groin, waist, behind ear |
| May be missed if not actively searched |
| Present in 40-80% cases |
| Location |
|---|
| Axilla |
| Groin / Inguinal area |
| Waistband area |
| Under breasts |
| Behind ears |
| Intergluteal fold |
| Scalp (in children) |
| System | Features |
|---|---|
|
Constitutional
|
High fever, headache, myalgia |
|
Skin
|
Eschar, maculopapular rash (trunk) |
|
Lymph nodes
|
Regional lymphadenopathy (near eschar) |
|
Respiratory
|
Cough, ARDS (common cause of mortality) |
|
CNS
|
Meningoencephalitis, altered sensorium |
|
Hepatic
|
Hepatomegaly, transaminitis |
|
Renal
|
AKI |
|
Cardiac
|
Myocarditis |
| Test | Timing | Notes |
|---|---|---|
|
Clinical (fever + eschar)
|
Any
|
Treat empirically if suspected |
|
IgM ELISA
|
Day 7+
|
Most useful; may be negative early |
|
Weil-Felix (OX-K)
|
Day 7+
|
Low sensitivity/specificity; avoid if possible |
|
PCR
|
Any
|
Expensive; limited availability |
| Drug | Dose | Route | Duration |
|---|---|---|---|
|
Doxycycline (First-line)
|
100 mg BD
|
PO or IV
|
Until afebrile for 3 days (min 7 days)
|
|
Azithromycin (Alternative)
|
500 mg OD
|
PO or IV
|
5-7 days
|
|
Azithromycin (Pregnancy/Children < 8 yrs)
|
10 mg/kg Day 1, then 5 mg/kg
|
PO
|
5 days
|
| Consideration | Current Recommendation |
|---|---|
| Age < 8 years |
May use Doxycycline for short courses in severe disease
|
| Dental staining risk | Minimal with short courses (< 21 days) |
| CDC/AAP | Doxycycline is drug of choice for rickettsial diseases in all ages |
| Alternative | Azithromycin 10 mg/kg/day |
| Clinical Scenario |
|---|
| Fever > 5 days without focus |
| Post-monsoon season |
| Rural/agricultural area or travel to endemic region |
| Eschar present |
| ARDS/Respiratory failure with fever |
| Multi-organ dysfunction with fever |
| Not responding to usual antibiotics |
| Complication | Management |
|---|---|
|
ARDS
|
Oxygen, ventilation, continue Doxycycline |
|
Shock
|
Fluids, vasopressors, Doxycycline |
|
Meningoencephalitis
|
IV Doxycycline, supportive |
|
Myocarditis
|
Supportive, Doxycycline |
|
AKI
|
Fluids, may need dialysis |
|
DIC
|
Supportive |
| Scenario | Action |
|---|---|
| Suspected (fever + eschar/endemic area) |
Start Doxycycline 100 mg BD immediately
|
| Mild disease | Doxycycline orally, monitor |
| Severe/MODS/ARDS |
IV Doxycycline + TRANSFER
|
| Pregnancy | Azithromycin 500 mg OD × 5 days |
| Child < 8 yrs (severe) | Doxycycline (CDC allows); OR Azithromycin |
| Feature | Details |
|---|---|
|
Cause
|
Leptospira interrogans (spirochete) |
|
Source
|
Urine of infected animals (rats, dogs, cattle) |
|
Transmission
|
Contact with contaminated water/soil through skin/mucosa |
|
Incubation
|
5-14 days |
|
Risk factors
|
Flooding, wading through water, agriculture, sewage work |
| Feature | Description |
|---|---|
|
Conjunctival suffusion
|
Redness without discharge – highly suggestive |
|
Muscle tenderness
|
Especially calf muscles |
|
Jaundice
|
Hepatorenal involvement |
|
Oliguria
|
Renal failure |
|
Hemorrhage
|
Pulmonary hemorrhage (severe form) |
| Form | Features | Mortality |
|---|---|---|
|
Anicteric (Mild)
|
Fever, myalgia, headache, conjunctival suffusion |
Low
|
|
Icteric (Weil's disease)
|
Jaundice + Renal failure + Hemorrhage |
5-15%
|
|
Pulmonary hemorrhage (SPHS)
|
Massive hemoptysis, ARDS |
50-70%
|
| Danger Sign |
|---|
| Jaundice |
| Oliguria / Anuria |
| Hemoptysis |
| Hypotension / Shock |
| Altered sensorium |
| Severe dyspnea |
| Bleeding manifestations |
| Test | Timing | Notes |
|---|---|---|
|
IgM ELISA
|
Day 5-7+
|
Most useful |
|
MAT (Microscopic Agglutination Test)
|
Day 10+
|
Gold standard but delayed |
|
Dark-field microscopy
|
First week
|
Low sensitivity |
|
PCR
|
First week
|
If available |
| Finding | Details |
|---|---|
| Leukocytosis | Often with neutrophilia |
| Thrombocytopenia | Mild-moderate |
| Elevated bilirubin | Direct hyperbilirubinemia |
| Elevated creatinine | Non-oliguric AKI common initially |
| Elevated transaminases | Usually < 5× ULN (unlike viral hepatitis) |
| Elevated CPK | Myositis |
| Abnormal urinalysis | Proteinuria, pyuria, casts |
| Severity | Drug | Dose | Duration |
|---|---|---|---|
|
Mild
|
Doxycycline |
100 mg BD PO
|
7 days
|
| OR Azithromycin |
500 mg OD PO
|
3-5 days
|
|
| OR Amoxicillin |
500 mg TID PO
|
7 days
|
|
|
Severe
|
Ceftriaxone |
1-2 g IV OD
|
7 days
|
| OR Penicillin G |
1.5 million units IV q6h
|
7 days
|
|
| OR Doxycycline |
100 mg IV BD
|
7 days
|
| Feature | Details |
|---|---|
| Timing | Within hours of first antibiotic dose |
| Features | Fever spike, rigors, hypotension, tachycardia |
| Cause | Release of bacterial toxins |
| Management | Supportive; does NOT mean stop antibiotics |
| Scenario | Action |
|---|---|
| Suspected (flood exposure + fever + myalgia ± jaundice) | Start Doxycycline 100 mg BD |
| Mild disease | Oral Doxycycline, monitor |
| Severe / Jaundice / Renal impairment |
IV Ceftriaxone 2g + TRANSFER
|
| Hemoptysis / ARDS |
IMMEDIATE TRANSFER
|
| Feature | Details |
|---|---|
|
Cause
|
Salmonella enterica serovar Typhi (or Paratyphi) |
|
Transmission
|
Fecal-oral (contaminated water/food) |
|
Incubation
|
7-21 days |
|
Key feature
|
Stepladder fever, relative bradycardia, hepatosplenomegaly |
| Week | Features |
|---|---|
|
Week 1
|
Gradually rising fever (stepladder), headache, malaise |
|
Week 2
|
High sustained fever, abdominal pain, hepatosplenomegaly |
|
Week 3-4
|
Complications: perforation, bleeding, encephalopathy |
| Sign | Description |
|---|---|
|
Stepladder fever
|
Gradually rising temperature over days |
|
Relative bradycardia
|
Pulse rate not matching fever (Faget sign) |
|
Coated tongue
|
White coating with red edges |
|
Hepatosplenomegaly
|
Soft, non-tender enlargement |
|
Rose spots
|
2-4 mm salmon-colored macules on trunk (uncommon) |
|
Abdominal tenderness
|
RIF (ileocecal region) |
| Test | Timing | Notes |
|---|---|---|
|
Blood culture
|
Week 1-2
|
Gold standard; sensitivity 60-80% |
|
Widal test
|
Week 2+
|
Unreliable; avoid if possible
|
|
Typhidot IgM
|
Day 4+
|
More reliable than Widal |
|
Stool culture
|
Week 2-3
|
Lower yield |
|
Bone marrow culture
|
Any
|
Highest yield; rarely done |
| Issue |
|---|
| Single titre unreliable (endemic areas have baseline positivity) |
| False positives: Other Salmonella, cross-reactions, infections |
| False negatives: Early disease, antibiotic use |
| Requires paired sera (acute + convalescent) for confirmation |
| Resistance Pattern | Current Status in India |
|---|---|
|
Fluoroquinolone (Cipro, Levo)
|
80-90% resistance/reduced susceptibility |
|
Chloramphenicol
|
Mostly sensitive now (resistance declined) |
|
Ampicillin
|
Variable (40-60% resistant) |
|
Cotrimoxazole
|
Variable |
|
Ceftriaxone
|
< 5% resistance (first-line) |
|
Azithromycin
|
< 5% resistance |
| Drug | Dose | Route | Duration |
|---|---|---|---|
|
Ceftriaxone (First-line)
|
2 g OD
|
IV
|
10-14 days
|
|
75 mg/kg/day (child)
|
IV
|
10-14 days
|
|
|
Azithromycin (Alternative)
|
500 mg OD (or 1 g Day 1 then 500 mg)
|
PO
|
7 days
|
|
20 mg/kg/day (child)
|
PO
|
7 days
|
|
|
Cefixime (Oral, mild cases)
|
200 mg BD
|
PO
|
14 days
|
|
20 mg/kg/day (child)
|
PO
|
14 days
|
| Drug | Dose | Route | Duration |
|---|---|---|---|
|
Ceftriaxone
|
2 g OD
|
IV
|
14 days
|
|
+ Consider Azithromycin
|
500 mg OD
|
IV/PO
|
7 days
|
|
For encephalopathy: Add Dexamethasone
|
3 mg/kg loading, then 1 mg/kg q6h
|
IV
|
48 hrs
|
| Complication | Timing | Management |
|---|---|---|
|
Intestinal perforation
|
Week 2-3
|
Surgical emergency |
|
GI bleeding
|
Week 2-3
|
Transfusion, surgery if massive |
|
Typhoid encephalopathy
|
Week 2-3
|
Dexamethasone + antibiotics |
|
Myocarditis
|
Variable
|
Supportive |
|
Relapse
|
Week 2 after stopping Rx
|
Repeat course of antibiotics |
|
Chronic carrier
|
After recovery
|
Prolonged antibiotics (4-6 weeks) |
| Scenario | Action |
|---|---|
| Suspected enteric fever (clinical + endemic area) | Ceftriaxone 2g IV OD OR Azithromycin 500 mg PO |
| Mild, tolerating orally | Azithromycin 500 mg OD × 7 days or Cefixime 200 mg BD × 14 days |
| Severe / Complications |
IV Ceftriaxone + TRANSFER
|
| Indication |
|---|
| Fever > 5 days with no clear focus |
| Endemic season (monsoon/post-monsoon) |
| Severe illness / Organ dysfunction |
| Clinical features suggestive of specific disease |
| Cannot wait for test results |
| Clinical Scenario | Empiric Treatment |
|---|---|
|
Fever + Eschar (any area)
|
Doxycycline 100 mg BD (Scrub Typhus)
|
|
Fever + Flood/water exposure + Myalgia ± Jaundice
|
Doxycycline 100 mg BD OR Ceftriaxone 2g (Leptospirosis)
|
|
Fever + Splenomegaly + Endemic area
|
RDT for Malaria → ACT if positive
|
|
Fever + Thrombocytopenia + Monsoon
|
Suspect Dengue; monitor closely; fluids |
|
Fever + Relative bradycardia + Hepatosplenomegaly
|
Ceftriaxone 2g (Enteric Fever)
|
|
Fever + ARDS/Multi-organ dysfunction
|
Doxycycline + Ceftriaxone (cover Scrub Typhus + Leptospirosis + Sepsis)
|
| Combination | Covers |
|---|---|
|
Doxycycline 100 mg IV BD + Ceftriaxone 2g IV OD
|
Scrub Typhus, Leptospirosis, Enteric Fever, Bacterial sepsis |
| Add Artesunate 2.4 mg/kg IV | If Malaria cannot be ruled out |
| Condition | Transfer Indication |
|---|---|
|
Dengue
|
Any warning sign, severe dengue, shock |
|
Malaria
|
Any danger sign, severe malaria |
|
Scrub Typhus
|
ARDS, shock, encephalitis, MODS |
|
Leptospirosis
|
Jaundice, renal failure, pulmonary hemorrhage |
|
Enteric Fever
|
Perforation, bleeding, encephalopathy |
|
Any
|
Not responding to treatment, deteriorating |
| Item | Done? |
|---|---|
| IV access secured |
โ
|
| IV fluids running (appropriate rate) |
โ
|
| Empiric antibiotics/antimalarials given |
โ
|
| Blood glucose checked |
โ
|
| Vital signs documented |
โ
|
| All investigations documented |
โ
|
| Receiving hospital pre-alerted |
โ
|
| Action | Target Time |
|---|---|
| Primary survey (ABCDE) |
Immediate
|
| Blood glucose |
≤ 5 min
|
| IV access (if not present) |
≤ 10 min
|
| Draw blood samples |
≤ 15 min
|
| Rapid tests (Dengue, Malaria) |
≤ 30 min
|
| Empiric treatment (if indicated) |
≤ 1 hour
|
| Investigation | Purpose |
|---|---|
|
CBC with differential
|
Thrombocytopenia, leukopenia/leukocytosis |
|
Peripheral smear
|
Malaria parasites, platelet count |
|
Malaria RDT
|
Rapid diagnosis |
|
Dengue NS1/IgM combo
|
Dengue confirmation |
|
Liver function (LFT)
|
Hepatic involvement |
|
Renal function (RFT)
|
AKI |
|
Blood glucose
|
Hypoglycemia (malaria) |
|
Electrolytes
|
Hyponatremia, hypokalemia |
|
Coagulation (PT, aPTT)
|
Coagulopathy |
|
ABG
|
Acidosis, oxygenation |
|
Blood cultures
|
Bacterial infection, enteric fever |
|
Urine analysis
|
Proteinuria (leptospirosis) |
|
Chest X-ray
|
ARDS, pulmonary edema, hemorrhage |
|
Lactate
|
Tissue perfusion |
|
Procalcitonin
|
Bacterial vs viral differentiation |
|
Scrub Typhus IgM
|
If suspected |
|
Leptospira IgM
|
If suspected |
| Category | Features |
|---|---|
|
Severe plasma leakage
|
Shock (DSS), fluid accumulation with respiratory distress |
|
Severe bleeding
|
GI bleeding, menorrhagia, etc. |
|
Severe organ impairment
|
Liver (AST/ALT > 1000), CNS (encephalopathy), Heart (myocarditis) |
| Step | Action |
|---|---|
| 1 |
Crystalloid bolus 10-20 mL/kg over 15-30 min
|
| 2 | Reassess (BP, pulse, Hct, urine output) |
| 3 | If improving: Reduce rate stepwise |
| 4 | If not improving: Repeat crystalloid bolus |
| 5 |
If still not improving: Colloid 10-20 mL/kg (Dextran 40 or Starch)
|
| 6 | If refractory: Blood transfusion if Hct falling |
| Time | Action |
|---|---|
|
0-1 hr
|
NS/RL 10-20 mL/kg over 1 hr |
|
1-2 hr
|
If improving: 10 mL/kg over 1 hr |
|
2-3 hr
|
If stable: 7 mL/kg/hr |
|
3-4 hr
|
Reduce to 5 mL/kg/hr |
|
Next
|
Stepwise reduction |
| Step | Action |
|---|---|
| 1 | Crystalloid bolus 20 mL/kg over 15-30 min |
| 2 | If no improvement: Repeat crystalloid 10-20 mL/kg |
| 3 | If still no improvement: Colloid 10-20 mL/kg |
| 4 | If Hct dropping: Blood transfusion |
| 5 | If Hct rising despite fluids: Consider more colloid |
| Hct Change | Interpretation | Action |
|---|---|---|
| Rising Hct | Ongoing plasma leak | More IV fluids |
| Falling Hct rapidly | Occult bleeding | Blood transfusion |
| Stable Hct | Adequate resuscitation | Maintain fluids |
| Packed RBCs | Significant bleeding + Hct drop | Hct > 30% |
|---|---|---|
|
Platelets
|
Active bleeding + platelets < 20,000 | — |
| Anticipated procedure + platelets < 50,000 | — | |
| โ NOT indicated prophylactically | — | |
|
FFP
|
Coagulopathy with bleeding | Correct PT/aPTT |
| Parameter | Frequency |
|---|---|
| Vitals (BP, HR, RR) |
Every 15-30 min in shock; hourly if stable
|
| Hct |
Every 4-6 hrs (more frequent in shock)
|
| Urine output |
Hourly (catheterize if needed)
|
| Blood glucose |
Every 4-6 hrs
|
| Platelet count |
Daily
|
| Clinical assessment |
Continuous
|
| Issue | Management |
|---|---|
|
Fluid overload
|
Stop IV fluids; oral fluids only; diuretics if needed |
|
Pulmonary edema
|
Diuretics, oxygen, reduce IV fluids |
|
Bradycardia
|
Normal in recovery; monitor |
|
Rash (confluent with islands of sparing)
|
Common; self-limiting |
| Timing | Dose |
|---|---|
|
0 hours
|
2.4 mg/kg IV
|
|
12 hours
|
2.4 mg/kg IV
|
|
24 hours
|
2.4 mg/kg IV
|
|
Then
|
2.4 mg/kg IV every 24 hrs
|
|
Duration
|
Until patient can take oral; minimum 24 hrs (3 doses)
|
|
Follow with
|
Oral ACT to complete 3 days
|
| Preparation | Details |
|---|---|
| Vial contents | 60 mg powder + solvent |
| Reconstitute | With 1 mL 5% sodium bicarbonate |
| Dilute | With 5 mL NS to get 10 mg/mL |
| Administration | IV bolus over 1-2 min OR IM |
| Weight (kg) | Dose (2.4 mg/kg) | Volume (10 mg/mL) |
|---|---|---|
| 40 |
96 mg
|
9.6 mL
|
| 50 |
120 mg
|
12 mL
|
| 60 |
144 mg
|
14.4 mL
|
| 70 |
168 mg
|
16.8 mL
|
| 80 |
192 mg
|
19.2 mL
|
| Complication | Management |
|---|---|
|
Cerebral malaria
|
Artesunate; avoid lumbar puncture if raised ICP; seizure control; nursing care |
|
Severe anemia (Hb < 5)
|
Blood transfusion; target Hb > 7 g/dL |
|
Hypoglycemia
|
50% dextrose 50 mL IV; D10% infusion; monitor closely |
|
AKI
|
Fluids; may need dialysis |
|
ARDS
|
Low tidal volume ventilation; minimize fluids |
|
Acidosis
|
Treat underlying cause; fluids; may need bicarbonate if pH < 7.1 |
|
Shock
|
Fluids; vasopressors; exclude gram-negative sepsis |
|
DIC
|
Supportive; blood products if bleeding |
|
Blackwater fever
|
Fluids; transfusion; stop quinine if being used |
| Feature | Details |
|---|---|
| Timing | 7-21 days after artesunate treatment |
| Mechanism | Delayed clearance of pitted RBCs |
| Features | Recurrent anemia, jaundice, hemolysis |
| Risk | More common in non-immune travelers; high parasitemia |
| Management | Monitor Hb weekly × 4 weeks; transfuse if needed |
| For P. falciparum | For P. vivax |
|---|---|
| Single dose 0.25 mg/kg after recovery | 14-day course 0.25 mg/kg/day after recovery |
| Gametocidal | Radical cure (anti-hypnozoite) |
| Check G6PD if possible | Check G6PD before 14-day course |
| Drug | Dose | Frequency | Duration |
|---|---|---|---|
|
Doxycycline
|
100 mg (or 2.2 mg/kg)
|
BD
|
at least until 3 days of fever resolution (min 7-14 days)
|
| Preparation | Details |
|---|---|
| Doxycycline vial | 100 mg powder |
| Reconstitute | With 10 mL sterile water |
| Dilute | In 100-250 mL NS or D5W |
| Infuse | Over 1-4 hours |
| โ ๏ธ Avoid | Rapid infusion (thrombophlebitis) |
| Therapy | Indication | Notes |
|---|---|---|
|
Steroids
|
ARDS, shock, myocarditis | Controversial; some use methylprednisolone 1-2 mg/kg |
|
Vasopressors
|
Refractory shock | Norepinephrine first-line |
|
Mechanical ventilation
|
ARDS | Lung-protective strategy |
|
Dialysis
|
AKI with indication | Standard RRT indications |
| Parameter | Frequency |
|---|---|
| Temperature |
Every 4-6 hrs
|
| Vitals |
Continuous/hourly if unstable
|
| SpOโ |
Continuous
|
| Urine output |
Hourly
|
| LFT, RFT |
Daily
|
| Chest X-ray |
Daily if ARDS
|
| Response | Timing |
|---|---|
| Defervescence | Within 24-48 hrs of Doxycycline |
| Clinical improvement | 48-72 hrs |
| If no response by 72 hrs | Reconsider diagnosis; ensure compliance |
| Severity | Drug | Dose | Duration |
|---|---|---|---|
|
Severe
|
Ceftriaxone |
1-2 g IV OD
|
7 days
|
| OR Penicillin G |
1.5 million units IV q6h
|
7 days
|
|
| OR Doxycycline |
100 mg IV BD
|
7 days
|
| Management | Details |
|---|---|
|
Antibiotics
|
IV Ceftriaxone or Penicillin immediately |
|
Oxygen
|
High-flow; may need intubation |
|
Mechanical ventilation
|
Lung-protective; PEEP |
|
Blood transfusion
|
If significant blood loss |
|
Steroids
|
Controversial; Methylprednisolone 1 g IV × 3 days used in some centres |
|
Plasma exchange
|
Case reports of benefit |
|
ECMO
|
Last resort |
| Feature | Management |
|---|---|
| Jaundice | Antibiotics; supportive |
| Hepatorenal syndrome | Fluids; dialysis if needed |
| Coagulopathy | Vitamin K, FFP if bleeding |
| Thrombocytopenia | Usually mild; transfuse if bleeding |
| Indication |
|---|
| Oliguria/anuria not responding to fluids |
| Severe hyperkalemia |
| Refractory acidosis |
| Uremic complications |
| Fluid overload |
| Drug | Dose | Duration |
|---|---|---|
|
Ceftriaxone
|
2 g IV OD (75 mg/kg/day in children)
|
10-14 days
|
|
+ Azithromycin (severe cases)
|
500 mg IV/PO OD
|
7 days
|
| Treatment | Dose |
|---|---|
|
Dexamethasone
|
3 mg/kg IV loading over 30 min
|
| Then |
1 mg/kg IV every 6 hrs × 8 doses (48 hrs)
|
| Continue |
IV Ceftriaxone
|
| Management |
|---|
| Surgical emergency |
| NPO |
| IV fluids |
| IV antibiotics (Ceftriaxone + Metronidazole) |
| Urgent surgery – primary repair or resection |
| Management |
|---|
| NPO |
| IV fluids |
| Blood transfusion if needed |
| Correct coagulopathy |
| Surgery if massive/uncontrolled |
| Scenario | Treatment |
|---|---|
|
Relapse (fever returns after stopping Rx)
|
Repeat full course of antibiotics |
|
Chronic carrier (stool positive > 1 year)
|
Ciprofloxacin 750 mg BD × 4 weeks OR Amoxicillin 2g TID + Probenecid × 6 weeks OR Cholecystectomy (if gallstones) |
| Coinfection | Scenario |
|---|---|
| Dengue + Malaria | Common in endemic areas during monsoon |
| Dengue + Scrub Typhus | Post-monsoon period |
| Scrub Typhus + Leptospirosis | Both post-monsoon; similar exposures |
| Malaria + Enteric Fever | Endemic areas |
| Principle | Action |
|---|---|
| Test for multiple diseases | Especially if atypical features |
| Treat for most life-threatening first | Malaria, Scrub Typhus |
| Combination empiric therapy | If undifferentiated and severe |
| Monitor response | Modify treatment based on results |
| Combination | Covers |
|---|---|
|
Ceftriaxone 2g IV OD
|
Enteric fever, Leptospirosis, Bacterial sepsis |
|
+ Doxycycline 100 mg IV BD
|
Scrub Typhus, Leptospirosis |
|
+ Artesunate 2.4 mg/kg IV
|
Malaria (if cannot be ruled out) |
| Parameter | Frequency |
|---|---|
| Vitals |
Continuous/hourly
|
| SpOโ |
Continuous
|
| Urine output |
Hourly
|
| Blood glucose |
4-6 hourly
|
| Hematocrit (Dengue) |
4-6 hourly
|
| Parasitemia (Malaria) |
Every 12-24 hrs until negative
|
| LFT, RFT, Coagulation |
Daily
|
| Aspect | Recommendation |
|---|---|
|
Fluids
|
Careful titration; avoid overload |
|
Glucose
|
Maintain euglycemia; D10% if hypoglycemic |
|
Electrolytes
|
Correct abnormalities |
|
Nutrition
|
Enteral preferred; start early if stable |
|
DVT prophylaxis
|
Mechanical (IPC); avoid pharmacological if bleeding risk |
|
Stress ulcer prophylaxis
|
PPI if high-risk |
|
Fever
|
Paracetamol; avoid NSAIDs in Dengue |
| Disease | Discharge Criteria |
|---|---|
|
Dengue
|
No fever × 48 hrs without antipyretics; improving appetite; stable Hct; platelets rising; no warning signs |
|
Malaria
|
Completed treatment; afebrile; tolerating orally; parasitemia clearing |
|
Scrub Typhus
|
Afebrile × 3 days; stable; completing oral Doxycycline |
|
Leptospirosis
|
Afebrile; renal function stable/improving; completing antibiotics |
|
Enteric Fever
|
Afebrile × 5-7 days; tolerating orally; no complications |
| Disease | Follow-up |
|---|---|
|
Dengue
|
Review in 1 week; watch for delayed recovery |
|
Malaria (Pf)
|
Day 28 smear; watch for PADH (Hb check weekly × 4) |
|
Malaria (Pv)
|
Complete Primaquine 14 days; watch for relapse |
|
Scrub Typhus
|
Complete antibiotics; watch for relapse |
|
Leptospirosis
|
Renal function check; complete antibiotics |
|
Enteric Fever
|
Stool culture to confirm clearance (especially food handlers) |
| Disease | First-Line | Alternative | Duration |
|---|---|---|---|
|
Scrub Typhus
|
Doxycycline 100 mg BD | Azithromycin 500 mg OD |
7-14 days
|
|
Leptospirosis
|
Ceftriaxone 2g IV OD | Doxycycline 100 mg BD |
7 days
|
|
Enteric Fever
|
Ceftriaxone 2g IV OD | Azithromycin 500 mg OD |
10-14 days
|
|
Severe Malaria
|
Artesunate 2.4 mg/kg IV | Artemether IM |
Until oral; then ACT
|
|
Uncomplicated Malaria (Pf)
|
ACT (Artesunate-Lumefantrine) | — |
3 days
|
|
Uncomplicated Malaria (Pv)
|
Chloroquine + Primaquine | ACT + Primaquine |
3d + 14d
|
|
Dengue
|
โ No antibiotics | — |
—
|
| Disease | Danger Signs → Transfer Immediately |
|---|---|
|
Dengue
|
Abdominal pain, persistent vomiting, fluid accumulation, mucosal bleeding, lethargy, Hct rise + plt drop, shock |
|
Malaria
|
Impaired consciousness, prostration, convulsions, respiratory distress, shock, Hb < 5, hypoglycemia, oliguria, jaundice |
|
Scrub Typhus
|
ARDS, shock, encephalopathy, multi-organ dysfunction |
|
Leptospirosis
|
Jaundice, oliguria, hemoptysis, shock, altered sensorium |
|
Enteric Fever
|
Encephalopathy, perforation (abdominal rigidity), massive GI bleed |
| Feature | Dengue | Malaria | Scrub Typhus | Leptospirosis | Enteric Fever |
|---|---|---|---|---|---|
|
Eschar
|
โ
|
โ
|
โ
|
โ
|
โ
|
|
Conjunctival suffusion
|
โ
|
โ
|
โ
|
โ
|
โ
|
|
Relative bradycardia
|
โ
|
โ
|
โ ๏ธ
|
โ
|
โ
|
|
Severe thrombocytopenia
|
โ
|
โ ๏ธ
|
โ ๏ธ
|
โ ๏ธ
|
โ ๏ธ
|
|
Jaundice
|
Rare
|
โ ๏ธ
|
โ ๏ธ
|
โ
|
Rare
|
|
Calf tenderness
|
โ
|
โ
|
โ
|
โ
|
โ
|
|
Splenomegaly
|
โ ๏ธ
|
โ
|
โ ๏ธ
|
โ ๏ธ
|
โ
|
|
ARDS
|
โ ๏ธ
|
โ ๏ธ
|
โ
|
โ
|
Rare
|
| โ NEVER | โ ALWAYS |
|---|---|
| Use NSAIDs/Aspirin in Dengue | Use Paracetamol for fever |
| Use Ciprofloxacin for Enteric Fever in India (80%+ resistance) | Use Ceftriaxone or Azithromycin |
| Give oral treatment for severe Malaria | Give IV/IM Artesunate for severe Malaria |
| Ignore eschar in fever | Search for eschar (hidden areas); treat for Scrub Typhus |
| Wait for serology to treat Scrub Typhus | Treat empirically with Doxycycline if suspected |
| Give prophylactic platelets in Dengue | Transfuse only for active bleeding + very low count |
| Forget Primaquine in P. vivax | Give 14-day Primaquine for radical cure (check G6PD) |
| Overload fluids in recovery phase of Dengue | Reduce fluids as patient improves |
| Situation | Remember |
|---|---|
| Monsoon fever + thrombocytopenia | Think Dengue first |
| Post-monsoon fever + eschar | Scrub Typhus until proven otherwise |
| Flood exposure + fever + jaundice | Leptospirosis |
| Endemic area + fever + splenomegaly | Malaria |
| Fever > 7 days + relative bradycardia | Enteric Fever |
| ARDS with fever in post-monsoon | Scrub Typhus or Leptospirosis |
| Undifferentiated severe fever | Doxycycline + Ceftriaxone ± Artesunate |
| Enteric fever antibiotics | NO Fluoroquinolones empirically |
| Abbreviation | Full Form |
|---|---|
|
ACT
|
Artemisinin-based Combination Therapy |
|
AL
|
Artesunate-Lumefantrine |
|
AS+SP
|
Artesunate + Sulfadoxine-Pyrimethamine |
|
RDT
|
Rapid Diagnostic Test |
|
NS1
|
Non-Structural Protein 1 |
|
DSS
|
Dengue Shock Syndrome |
|
Hct
|
Hematocrit |
|
PADH
|
Post-Artesunate Delayed Hemolysis |
|
G6PD
|
Glucose-6-Phosphate Dehydrogenase |
|
SPHS
|
Severe Pulmonary Hemorrhage Syndrome |
|
MAT
|
Microscopic Agglutination Test |
|
ARDS
|
Acute Respiratory Distress Syndrome |
|
MODS
|
Multi-Organ Dysfunction Syndrome |
|
AKI
|
Acute Kidney Injury |
|
DIC
|
Disseminated Intravascular Coagulation |
|
RFT
|
Renal Function Tests |
|
LFT
|
Liver Function Tests |
|
Pf
|
Plasmodium falciparum |
|
Pv
|
Plasmodium vivax |
|
JE
|
Japanese Encephalitis |
|
NVBDCP
|
National Vector Borne Disease Control Programme |
|
IPC
|
Intermittent Pneumatic Compression |
|
FFP
|
Fresh Frozen Plasma |
|
NS
|
Normal Saline |
|
RL
|
Ringer's Lactate |
|
OD
|
Once Daily |
|
BD
|
Twice Daily |
|
TID
|
Three Times Daily |
|
q6h
|
Every 6 hours |
| Guideline/Source | Year |
|---|---|
| WHO Guidelines on Dengue |
2009, 2012
|
| National Guidelines on Dengue (NVBDCP, India) | 2022 |
| WHO Guidelines on Severe Malaria |
2015, 2021
|
| National Framework for Malaria Elimination (India) | 2016 |
| ICMR Guidelines on Scrub Typhus | 2021 |
| IAP-RCPCH Guidelines on Scrub Typhus | 2021 |
| WHO Guidelines on Leptospirosis | 2003 |
| ICMR Antimicrobial Resistance Surveillance | 2022 |
| API Textbook of Medicine |
Latest Edition
|
| Indian Journal of Medical Research – Tropical Fever Reviews |
Various
|
Medical Advisory
Clinical guidelines are subject to change. Physicians should exercise their regular clinical judgment. This protocol does not replace individual institutional policies. Verified for Q1 2026.
Help us improve our clinical database for the medical community.